A late-stage trial found that adding Amgen's Imdelltra to AstraZeneca's Imfinzi immunotherapy reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer, extending median survival to 21.1 months from 12.7 months with Imfinzi alone. This aggressive cancer often spreads beyond the lungs and is hard to treat, but the combination shows promise in turning it into a more manageable condition. The drugs work together by activating the immune system to better attack cancer cells. These results could change the standard of care and expand Imdelltra's use earlier in treatment, potentially improving outcomes for many patients.
Amgen's stock price at USD 439.26 is trading close to its 52-week high of USD 447.28, while AstraZeneca is further from its peak, priced at USD 171.49 against a 52-week high of USD 209.48 as of Oct 24, 2026 21:41 WIB. Despite the promising trial results for their drug combo, both stocks saw declines on the day, with Amgen down 1.79% and AstraZeneca down 0.63%. On Pluang, Amgen has a higher dividend yield of 2.29% compared to AstraZeneca's 1.87%, and Amgen's shares tend to be held for a shorter average time of 73 days versus 126 days for AstraZeneca.
Amgen announced Phase 3 DeLLphi-305 trial results where IMDELLTRA combined with AstraZeneca's IMFINZI reduced death risk by 58% and extended median overall survival to 21.1 months in extensive-stage small cell lung cancer patients. Nearly 80% of pati...
Amgen will hold a webcast on October 24, 2026, during the European Society of Medical Oncology Congress (ESMO) to discuss its oncology portfolio and present selected data. The event will feature senior executives including Murdo Gordon and Jean-Charl...
Eli Lilly's stock rose 4% following a positive recommendation from the European Medicines Agency for its oral obesity pill, Foundayo, which is now close to final approval in the EU. This pill offers dosing flexibility and treats both weight managemen...
Amgen and AstraZeneca announced positive Phase 3 CROSSING trial results for TEZSPIRE (tezepelumab-ekko), demonstrating significant and lasting improvements in patients with eosinophilic esophagitis (EoE). The drug achieved histologic remission in abo...
